August 28, 2016 6:26 AM ET

Biotechnology

Company Overview of TELA Bio, Inc.

Company Overview

TELA Bio, Inc. operates in healthcare industry focusing on biotechnology business. The company was founded in 2012 and is based in Malvern, Pennsylvania.

1 Great Valley Parkway

Suite 24

Malvern, PA 19355

United States

Founded in 2012

Phone:

484-320-2930

Key Executives for TELA Bio, Inc.

President and Chief Executive Officer
Age: 50
Compensation as of Fiscal Year 2016.

TELA Bio, Inc. Key Developments

TELA Bio, Inc Launches OviTex Reinforced BioScaffolds for Ventral Hernia Repair and Abdominal Wall Reconstruction

TELA Bio, Inc. announced the commercial launch of the company's OviTex portfolio of products for use in ventral hernia repair and abdominal wall reconstruction following U.S. Food and Drug Administration (FDA) 510(K) clearance. OviTex RBSs feature an embedded polymer and an intact extracellular matrix (ECM), a biologic building block derived from ovine rumen, in layered constructs designed for multi-directional cell repopulation and healthy tissue remodeling. The OviTex portfolio includes six products with a range of sizes, thicknesses, and degrees of reinforcement that allows surgeons to choose the appropriate product for each procedure and surgical technique. OviTex RBSs are available with either permanent (polypropylene) polymer or resorbable (polyglycolic acid) polymer reinforcement. The FDA granted 510(K) clearance for the resorbable polymer products in March 2016 and recently granted the same clearance for permanent polymer products in June 2016. The company is poised to enroll post-market clinical studies following initial commercialization.

Lifecell Obtains Preliminary Injunction Preventing TELA Bio’s Launch of its TELAMax Hernia Mesh

Acelity announced that the Superior Court of New Jersey, Somerset County, has granted LifeCell Corporation's request for a preliminary injunction in a trade secret and unfair competition case against TELA Bio, Inc. and two of its executive officers. The preliminary injunction (Case No. SOM-C-12013-15) prohibits TELA Bio from selling TELAMax, its hernia mesh product, in the United States until the completion of a trial, which has not yet been scheduled. In addition, the injunction prevents TELA Bio from recruiting or hiring current or former LifeCell employees and restrains TELA Bio from destroying evidence in this case. The injunction was granted based on a complaint filed by LifeCell in March alleging, among other things, that TELA Bio and two of its founders misappropriated trade secrets and proprietary information and engaged in unfair competition. The Court initially granted a temporary restraining order against TELA Bio in March, and following a hearing on April 30, the Court granted LifeCell's request for a preliminary injunction on May 8, 2015.

Similar Private Companies By Industry

Company Name Region
20n Labs, Inc. United States
23andMe, Inc. United States
2C Tech Corporation, Inc. United States
3-V Biosciences, Inc. United States
3D Bio Holdings LLC United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

The information and data displayed in this profile are created and managed by Capital IQ, a Standard & Poor's company. Bloomberg.com does not create or control the content. For inquiries, please contact Capital IQ directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Bloomberg L.P. United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact TELA Bio, Inc., please visit www.telabio.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.